Pertuzumab biosimilar (Qilu Pharmaceutical)

帕妥珠单抗生物类似药（齐鲁制药）

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePertuzumab biosimilar (Qilu Pharmaceutical)
Drug Alias Name安赛珠QL-1209QL1209
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/12/17
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A